Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS. - Miller, T.; Cudkowicz, M.; Shaw, P. J.; Andersen, P. M.; Atassi, N.; Bucelli, R. C.; Genge, A.; Glass, J.; Ladha, S.; Ludolph, A. L.; Maragakis, N. J.; McDermott, C. J.; et al. (New England Journal of Medicine, 2020)